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Abstract
Background: SIR2 is an NAD
+-dependent deacetylase [1–3] implicated in the regulation of lifespan in species as diverse as
yeast [4], worms [5], and flies [6]. We previously reported that the level of SIRT1, the mammalian homologue of SIR2 [7,8], is
coupled to the level of mitotic activity in cells both in vitro and in vivo [9]. Cells from long-lived mice maintained SIRT1 levels
of young mice in tissues that undergo continuous cell replacement by proliferating stem cells. Changes in SIRT1 protein
level were not associated with changes in mRNA level, suggesting that SIRT1 could be regulated post-transcriptionally.
However, other than a recent report on sumoylation [10] and identification of SIRT1 as a nuclear phospho-protein by mass
spectrometry [11], post-translational modifications of this important protein have not been reported.
Methodology/Principal Findings: We identified 13 residues in SIRT1 that are phosphorylated in vivo using mass
spectrometry. Dephosphorylation by phosphatases in vitro resulted in decreased NAD
+-dependent deacetylase activity. We
identified cyclinB/Cdk1 as a cell cycle-dependent kinase that forms a complex with and phosphorylates SIRT1. Mutation of
two residues phosphorylated by Cyclin B/Cdk1 (threonine 530 and serine 540) disturbs normal cell cycle progression and
fails to rescue proliferation defects in SIRT1-deficient cells [12,13].
Conclusions/Significance: Pharmacological manipulation of SIRT1 activity is currently being tested as a means of extending
lifespan in mammals. Treatment of obese mice with resveratrol, a pharmacological activator of SIRT1, modestly but
significantly improved longevity and, perhaps more importantly, offered some protection against the development of type
2 diabetes mellitus and metabolic syndrome [14–16]. Understanding the endogenous mechanisms that regulate the level
and activity of SIRT1, therefore, has obvious relevance to human health and disease. Our results identify phosphorylation by
cell cycle dependent kinases as a major mechanism controlling the level and function of this sirtuin and complement recent
reports of factors that inhibit [17,18] and activate [19] SIRT1 by protein-protein interactions.
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Introduction
The SIR2 gene encodes an NAD
+-dependent deacetylase [1–3].
It was first identified in yeast as a gene involved in mating type
switching [20], but is now known to be a highly conserved gene in
organisms ranging from archea to humans [21]. Of the seven SIR2
family homologues (sirtuins) in humans [7,8], SIRT1 is most
closely related to the SIR2 gene of Saccharomyces cerevisiae [8]. Over-
expression of SIR2 extends replicative life-span in yeast [4], and
orthologs extend organismal life-span in both worms and flies
[5,6]. Recently, it was shown that resveratrol, a pharmacological
activator of SIRT1, can improve the life span and health of mice
on a typical ‘‘western’’ (high-calorie) diet [15,16].
We previously reported that the level of SIRT1 is coupled to the
level of mitotic activity in cells both in vitro and in vivo [9]. Changes
in SIRT1 protein level were not associated with changes in mRNA
level, suggesting that SIRT1 could be regulated post-transcrip-
tionally. However, other than phosphorylation of serine 27 and
serine 47, which were detected in general screens of nuclear
phospho-proteins by mass spectrometry [11] and sumoylation of
lysine 734 [10], post-translational modifications of this important
protein have not been reported.
In this work, we investigated the connection between SIRT1
protein levels and mitotic activity by determining if there was a
direct effect of mitotic cell cycle kinases on SIRT1 phosphoryla-
tion. In somatic cells, cyclin D/Cdk 4,6 is active during the
progression through G1 and into S phase. Cyclin E/Cdk 2
complex becomes active at late G1 phase into S phase. CyclinA/
Cdk2 becomes active during S phase, and the CyclinB/Cdk1
complex is activated upon passing the G2/M checkpoint and
inactivated upon entry into anaphase [22]. We also explored the
hypothesis that phosphorylation might regulate the deacetylase
activity of SIRT1, as it is known to do with other classes of protein
deacetylases, such as HDAC1 and HDAC2 [23,24]. As described
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4020below, we found that SIRT1 is phosphorylated by cyclinB/Cdk1,
and that phosphorylation regulates its deacetylase activity and
affects cell proliferation.
Results
SIRT1 is phosphorylated at 13 residues in vivo
To determine if SIRT1 is a phosphoprotein, we stained gels
containing affinity-purified FLAG-SIRT1 separated by SDS-
PAGE with Pro-Q Diamond phosphoprotein reagent. We also
performed western analysis using an antibody that detects the
phosphorylated serine residue in the consensus Cdk recognition
motif (K/R-S*-P-x-K/R). As shown in Fig. 1A, both the anti-
phospho serine Cdk substrate antibody and the ProQ reagent
detect a protein that migrates to the same position in the gel as
FLAG-SIRT1 (120 kD; lane marked ‘‘-’’). The signals decreased
in a dose-dependent manner following treatment with lambda
protein phosphatase (lppase). Although reaction with the anti-
phospho serine Cdk substrate antibody was lost at a low dose of
lppase, some reactivity with the phosphoprotein stain, which
detects all phospho-residues, was still visible even after treatment
with high doses of lppase and required overnight treatment for
complete removal. This difference in sensitivity to lppase
treatment of the two detection methods implied that SIRT1 could
be phosphorylated at multiple residues, and could contain
phospho-threonine and phospho-tyrosine residues in addition to
phospho-serine.
To identify the residues of SIRT1 that are phosphorylated in
vivo, we analyzed affinity-purified FLAG-SIRT1 by mass spec-
trometry. The analysis revealed 13 phosphorylation sites
(Table 1), including threonine 530 and serine 540. Phosphory-
lation was restricted to serine and threonine residues; there were
no phosphorylated tyrosine residues in the samples examined. All
of the identified phosphorylation sites are located in either the N-
terminal domain or the C-terminal domain of SIRT1, and not in
the conserved catalytic core domain (Fig. 1B). To illustrate how
the phosphorylation sites could potentially regulate substrate
access and protein interactions, we used the known amino acid
sequence of SIRT to derive a full chain protein structure
prediction based on homology and ab initio modeling using the
Robetta server (Baker Laboratory, http://robetta.bakerlab.org/).
As shown in Fig. 1C, the structure predicts an extensive clustering
of phosphorylation sites on residues in the carboxy terminal
domain (yellow) adjacent to the Rossmann fold (red) that supports
the catalytic groove in the core domain (blue). Phosphorylation of
residues in the amino terminal domain (green) are less likely to be
directly involved in regulating enzyme activity.
Cyclin recognition motifs and Cdk substrate residues are
conserved among orthologs of SIRT1
To determine if the phosphorylation sites identified by mass
spectrometry were evolutionarily conserved, we compared the
amino acid sequences surrounding each phosphorylated residue in
12 different species (Table 2). Among the phosphorylated residues
listed in Table 1, Ser159, Ser162, Ser172, Ser173, Thr530,
Ser535, Ser538, and Ser540 are relatively well conserved. A cyclin
recognition motif and a Cdk substrate motif together constitute a
bipartite substrate recognition sequence for cyclin-dependent
kinases [25]. Ser540 fits the full consensus sequence for a Cdk
substrate (S/T*-P-x-K/R), and Thr530 fits the minimal consensus
sequence for a Cdk substrate (S/T*-P) [26–28]. Two cyclin
recognition motifs (located between amino acid 203–207 and 519–
523) are also well conserved. Some of the phosphorylation sites are
not conserved because the N-terminal and the C-terminal domains
Figure 1. SIRT1 is a phosphoprotein. A. Affinity-purified SIRT1 is phosphorylated, and can be dephosphorylated by lppase. Top panel, western
blot of total SIRT1; middle panel, western blot of SIRT1 phosphorylated at the Cdk consensus site; bottom panel, ProQ-diamond stained blot showing
total phosphorylated SIRT1. Numbers above the lanes indicate the relative doses of lppase used to treat FLAG-SIRT1 for 1 hour. Overnight treatment
(O/N) was done with a 1/10 dilution of lppase. B. Schematic of the phosphorylated residues in SIRT1 identified by mass spectrometry, as shown in
Table 1. P, phosphorylated residue. C. 3D structure prediction of full-length human SIRT1 with the positions of phosphorylated residues identified
by mass spectrometry (red symbols). Amino terminal domain, green; catalytic core domain, blue; carboxy terminal domain, yellow. The Rossmann
fold supporting the catalytic groove in the core domain is shown in red. The two mutated residues described in the text (Thr530 and Ser540) are
indicated with asterisks.
doi:10.1371/journal.pone.0004020.g001
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sites that fit the minimal consensus sequence for Cdk substrates,
such as Ser14, Ser26/27, Ser47 and Ser545, are only conserved in
higher organisms.
SIRT1 deacetylase activity is modulated by
phosphorylation
To test the possibility that the phosphorylation of SIRT1 might
modulate its NAD
+-dependent deacetylase activity, we compared
the enzymatic activity of phosphorylated and dephosphorylated
affinity-purified FLAG-SIRT1using afluorogenicpeptide-substrate-
based assay system, Fluor-de Lys [29]. Dephosphorylation by calf
intestinal phosphatase (CIP; Fig. 2A) or lambda phosphatase
(lppase; Fig. 2B) led to a decline in deacetylase activity. This
decline was associated with complete dephosphorylation at the Cdk
sites in SIRT1, as shown in the accompanying images of western
blots analyzed with an antibody against phosphorylated Cdk
recognition sites. Neither the deacetylase activity nor the reaction
with the anti-phosphoserine Cdk substrate antibody decreased when
phosphatase activities were blocked (lanes marked ‘‘+inhibitor’’).
Therefore, the general loss of SIRT1 phosphorylation leads to a
decline in its deacetylase activity. To rule out the possibility that
changes in deacetylase activity were due to the activity of other
classes of histone deacetylases, which are NAD
+-independent,
contaminating the FLAG-SIRT1 preparation, we repeated the
Fluor-de Lys deacetylase assay in the absence of NAD
+. As shown in
Fig. 2C, there was no measurable deacetylase activity in the FLAG-
SIRT1 preparation unless NAD
+ was added to the reaction.
SIRT1 forms a complex with cyclinB and Cdk1 in vivo
To determine if the highly conserved cyclin/Cdk substrate
motifs at Thr530 and Ser540, which we found to be phosphor-
ylated in vivo, are substrates for the enzyme, we transfected 293T
cells with a FLAG-SIRT1 expression vector and prepared cell
lysates from cells in exponential growth phase. We immunopre-
cipitated SIRT1 using anti-FLAG M2 beads and analyzed the
immune complexes by western blot. We found Cdk1 in immune
complexes with FLAG-SIRT1 (Fig. 3A). Cdk1 is a G2/M phase
kinase that interacts with cyclinA and cyclinB to regulate mitosis
[22]. We found that cyclinB, but not cyclinA, was detectable in a
complex with FLAG-SIRT1 in asynchronously growing cultures
(Fig. 3A). This interaction was specific, as no cyclin or Cdk
proteins were immunoprecipitated when non-specific protein-G
beads were substituted for the FLAG M2-specific beads (Fig. 3A,
lanes marked ‘‘ProG’’). The relatively low percentage of cyclinB
detected in immune complexes reflects the relatively small number
of cells in M-phase in these cultures, which could account for our
inability to detect cyclinA in immune complexes with SIRT1 and
Cdk1 as well. It is also possible that G1-associated kinases, such as
Cdk2, Cdk4 and Cdk6, interact with SIRT1 at levels we could not
detect, but this is less likely due to the relative abundance of cells in
G1even in asynchronized cultures. Next, we performed co-
immunoprecipitations from extracts of embryonic stem cells
(ESCs) to determine if complexes between SIRT1 and Cdk1 and
cyclinB also formed between endogenous proteins. As shown in
Fig. 3B, antibodies against both N- and C-terminal epitopes of
SIRT1 precipitated endogenous Cdk1 and cyclinB along with
endogenous Sirt1 in ESCs. This interaction was specific, as no
proteins were immunoprecipitated when non-specific protein-G
beads were substituted for the FLAG M2-specific beads (Fig. 3B,
lanes marked ‘‘ProG’’). Compared to MEFs, a higher proportion
of cyclinB was co-precipitated with SIRT1, reflecting the high
proportion of ESCs that are in M-phase even in asynchronously
growing cultures.
SIRT1 is phosphorylated by cyclinB/Cdk1 in vitro
To determine if cyclinB/Cdk1 could phosphorylate SIRT1, we
performed in vitro kinase assays with affinity-purified human
FLAG-SIRT1, using histone H1, a known substrate for cyclinB/
Cdk1, as a positive control. We found that SIRT1 is an excellent
substrate for phosphorylation by cyclinB/Cdk1 in vitro (Fig. 4A–
B). We think that endogenous SIRT1 is also phosphorylated by
this cyclin/cdk complex, although the reagents necessary to verify
this experimentally are currently not available. Recombinant
SIRT1, on the other hand, was a poor substrate (data not shown),
probably reflecting a requirement for second-site phosphorylation,
Table 1. Phospho-peptide mapping of FLAG-SIRT1 by mass spectrometry.
Sequence of Identified Peptides Sites
MADEAALALQPGGS*PSAAGADR S14
EAAS*SPAGEPLR S26
EAASS*PAGEPLR S27
MADEAALALQPGGS*PSAAGADREAAS?S?PAGEPLR S14, and S26 or S27
S*PGEPGGAAPER S47
DNLLFGDEIITNGFHS?CES?DEEDR S159 or S162
ASHASS*SDWTPRPR S173
ASHAS*S*SDWTPRPR S172 and S173 likely (2 out of 3 sites within S172–S174)
ELAYLSELPPT*PLHVSEDSSSPER T530
ELAYLSELPPTPLHVSEDS?S?S?PER 1 of 3 sites within S538–S540
ELAYLSELPPTPLHVS?EDS?S?S?PER 2 of 4 sites within S535 and S538–S540
T?S?PPDSSVIVTLLDQAAK T544 or S545
AGGAGFGT*DGDDQEAINEAISVK T719
QEVTDMNYPSNKS* S747
Phosphorylation is indicated by an asterisk (*). A site that could not be ruled out is indicated by a question mark (?). Two independent samples of affinity-purified FLAG-
SIRT1 were analyzed. The results were consistent between the two, except for S747 phosphorylation, which was detected in only one of the samples.
doi:10.1371/journal.pone.0004020.t001
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protein. To test the requirement for second-site phosphorylation
directly, we subjected affinity-purified FLAG-SIRT1 to global
dephosphorylation, then treated the dephosphorylated substrates
with cyclinB/Cdk1. Phosphorylation at Cdk recognition sites in
SIRT1 decreased as the dose of lppase increased, and was
abolished when SIRT1 was maximally dephosphorylated
(Fig. 5A). The level of phosphorylation at Cdk sites was higher
in extracts with added cyclinB/Cdk1 than in extracts with no
added kinase (compare left- and right-hand panels). Next, we
performed a second in vitro kinase assay using radioactive ATP to
detect protein phosphorylation by cyclinB/Cdk1. After treatment
with higher doses of lppase, there was minimal incorporation of
radioactive phosphate into SIRT1 (Fig. 5C). Histone H1,
however, which is not affected by second-site phosphorylation,
was efficiently labeled by radioactive ATP even at the highest
doses of lppase. These data imply that additional phosphorylation
sites increase the suitability of SIRT1 as a substrate for cyclinB/
Cdk1. To test this, we used a mitotic kinase mix, which contains
high levels of several mitotic-phase kinases in addition to cyclinB/
Cdk1 [30], to phosphorylate FLAG-SIRT1. In the presence of
these additional kinases, SIRT1 was maximally phosphorylated
(Fig. 5C).
Threonine 530 and serine 540 of SIRT1 are targets for
cyclinB/Cdk1 in vitro
To test the hypothesis that Thr530 and Ser540 are cyclinB/
Cdk1 substrates directly, we mutated each site to a non-
phosphorylatable amino acid (alanine), then tested whether or
not the mutant proteins could be phosphorylated by cyclinB/Cdk1
in vitro. Mutation of either Ser540RAla or Thr530RAla or both
had no effect on protein stability or localization (Fig. 6A–B).
However, compared to wild type, the S540A mutant showed
approximately 50% reduction in the incorporation of radioactive
ATP and the T530A and T530A/S540A double mutant (AA)
showed approximately 35% reduction (Fig. 6C–D), indicating
that both residues are substrates for cyclinB/Cdk1 in vitro. The fact
that the radioactive signal decreased in the mutants, but did not go
away completely, indicates that other less well-conserved residues
that fit the minimal Cdk substrate motif, such as Ser14, Ser27,
Ser47 and Ser545 (Table 2) may also be substrates for cyclinB/
Cdk1 in vitro.
Phosphorylation of SIRT1 at Thr530 and Ser540
influences cell proliferation and cell cycle profiles
To determine if the decline in deacetylase activity associated
with global dephosphorylation of SIRT1 was linked to changes in
phosphorylation at Thr530 and/or Ser540, we compared the
deacetylase activity in preparations of FLAG-SIRT1 with or
without the T530A and/or S540A mutations. We found no
significant differences in the NAD
+-dependent deacetylase activity
(data not shown). However, another possible function of SIRT1
phosphorylation by cell cycle-regulated kinases was suggested by
our previous finding that cell proliferation fluctuates with the level
of SIRT1 in cells and tissues (Sasaki 2006). To test the significance
of SIRT1 on cell proliferation, we transfected Sirt1-deficient
mouse cells with expression vectors for normal FLAG-SIRT1
(WT) or FLAG-SIRT1 with the T530A/S540A mutation (AA).
We found that the proliferation defects of Sirt1
2/2 MEFs (Fig. 7A,
left-hand panel) and ES cells (Fig. 7B, left-hand panel) could be
rescued by transfection of WT SIRT1, but not by the T530A/
S540A double mutant (Fig. 7A–B, right-hand panels). These
effects on proliferation were not due to large differences in protein
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Fig. 7C–D for MEFs, and ESCs, respectively.
To determine which phase of the cell cycle was affected by loss
of Sirt1, we compared the cell cycle profiles of wild-type and Sirt1-
deficient ES cells. Cells were stained with propidium iodide and an
anti-phospho-histone H3 (Ser10) antibody that is detected only
during mitosis [31]. Although we expected that phosphorylation
by Cdk1, an M-phase kinase, would alter the percentage of
Sirt12/2 ES cells in M-phase, there was no difference compared
to Sirt1+/+ ES cells (Fig. 8A). We did find that Sirt12/2 ES cells
have a small, but statistically significant, increase in the proportion
of cells in S-phase compared to wild-type (Fig. 8B; compare
mock-transfected Sirt+/+ and 2/2 ES cells). To determine if this
was due to Cdk1-dependent phosphorylation of mouse Sirt1, we
Figure 2. NAD
+-dependent deacetylase activity of SIRT1 is
modulated by phosphorylation. A/B. NAD
+-dependent deacetylase
activity of SIRT1 in the presence of CIP (A)o rlppase (B) with or without
phosphatase inhibitors. Western blots below each bar graph indicate
the amount of SIRT1 in the reaction (top panel) and the degree of SIRT1
phosphorylation represented by Cdk-pSer signal (bottom panel). C.
Deacetylase activity of affinity-purified FLAG-SIRT1 in the presence (left)
or absence (right) of NAD
+. Blue bars, no nicotinamide added; red bars,
+ nicotinamide. *, p,0.005; **, p,0.02; ***, p,0.002; #,p ,0.01; ##,
p,0.001 (Student’s t-test). Error bars indicate +/2SEM.
doi:10.1371/journal.pone.0004020.g002
Figure 3. SIRT1 forms a complex with cyclinB/Cdk1. A. Western
blot analysis of different Cdks and Cyclins following co-IP with FLAG-
SIRT1. Complex formations of FLAG-SIRT1 with Cdk1 and cyclinB were
detected, but not with Cdk2, Cdk4, Cdk6, or cyclinA. Amounts of
samples used: whole cell extract (WCE), 20 mg; IP 500 mg. B. Western
blot of co-IP experiments with endogenous SIRT1, which also forms a
complex with Cdk1 and cyclinB. Amounts of samples used: WCE, 20 mg;
IP 1.5 mg. WCE, whole cell extracts; IP, immunoprecipitation; FLAG,
FLAG-M2 beads.
doi:10.1371/journal.pone.0004020.g003
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vectors encoding wild-type or mutant (AA) human SIRT1 and
again analyzed the cell cycle by FACS. We found that wild-type
SIRT1 could rescue the increase in S-phase cells, but the AA
mutant could not. The percentages of cells in G1 and G2/M were
also significantly different in Sirt1-deficient ES cells transfected
with wild-type and mutant SIRT1 (Fig. 8C). Rescue of the G2/
M-phase difference identified in mock-transfected Sirt1+/+ and
Sirt12/2 cells (Fig. 8B; green) was due to rescue of G2 deficits
by wild-type but not mutant SIRT1, consistent with our finding
that M-phase in Sirt12/2 ES cells was normal (Fig. 8A). In
summary, phosphorylation of SIRT1 by cyclinB/Cdk1 is
necessary for progression through the cell cycle, apparently by
facilitating entry into G2. Cell proliferation is impaired to the same
extent by blocking Cdk1 phosphorylation of SIRT1 and by
complete loss of SIRT1. Together with data indicating that
dephosphorylation decreases SIRT1 deacetylase activity, these
studies reveal a critical role for phosphorylation in regulating
SIRT1 function.
Discussion
In this paper, we provide an explanation for our previous
finding that increases in SIRT1 protein when cells are mitotically
active are not the result of increased SIRT1 transcription (Sasaki
T, et al. 2006). We have identified 13 serine and threonine residues
in SIRT1 that are phosphorylated, and we demonstrated that one
of the kinases that can phosphorylate SIRT1 is the cell cycle-
dependent kinase Cdk1. Thus, post-transcriptional modification
by phosphorylation appears to play a significant role in increasing
the level of SIRT1 protein in cycling cells.
Figure 5. SIRT1 requires phosphorylation to become a suitable
substrate for cyclinB/Cdk1 in vitro. A. Western blots of Cdk-
phosphorylated (top panel) and total SIRT1 (bottom panel) following
treatment with increasing doses of lambda phosphatase (lppase). The
upper band corresponds to the full-length SIRT1. B. Levels of SIRT1
phosphorylation at Cdk-specific sites in extracts used as substrates for
in vitro kinase assays shown in C. C. Autoradiographs (top panels) and
Coomassie blue-stained gels (bottom panels) of SIRT1 and histone H1
phosphorylated by the kinases indicated on left. 0, 0.01, 0.1, 1, relative
doses of lppase used; %P, relative percentage of Cdk phospho-serine
signal compared to control.
doi:10.1371/journal.pone.0004020.g005
Figure 4. SIRT1 is phosphorylated by cyclinB/Cdk1 in vitro. A.
Autoradiographs of radioactively labeled proteins separated by SDS-
PAGE (upper panels) and pictures of Coomassie blue-stained gels (lower
panels). Substrates are indicated to the left of each pair of panels. B.
ATP incorporation vs. time. ATP incorporation was determined by
scintillation counting of the radioactivity in each band.
doi:10.1371/journal.pone.0004020.g004
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PLoS ONE | www.plosone.org 7 December 2008 | Volume 3 | Issue 12 | e4020Some of the phosphorylated residues, cyclin-recognition motifs,
and Cdk substrate motifs identified in our search are conserved
among species. An in depth analysis revealed an interesting aspect
of these conserved residues as they relate to organisms that, unlike
mammals, consist mainly of post-mitotic cells as adults. The
residue that corresponds to Ser540 in human SIRT1 is E
(glutamate) in D. melanogaster and D (aspartate) in C. elegans.
SRD and SRE mutations are commonly used as phospho-
mimetics, suggesting that, in cells no longer undergoing mitosis,
the function of SIRT1 affected by phosphorylation at this residue
Figure 7. Phosphorylation of SIRT1 at Thr530 and Ser540 affects cell proliferation. Proliferation of Sirt1
+/+ and Sirt1
2/2 MEFS (A) and ES
cells (B) and in cells transfected with wild-type (WT) or mutant (AA) SIRT1. Representative experiments are shown. Each experiment was performed in
triplicate and was repeated a minimum of two times. The differences were significant to varying degrees depending on the experiment and are
indicated with an asterisk. Western blot analysis was used to ensure that the levels of expression of wild type or mutant SIRT1 proteins in transfected
MEFs (C) and ESCs (D) were equivalent.
doi:10.1371/journal.pone.0004020.g007
Figure 6. Threonine 530 and serine 540 of SIRT1 are substrates for cyclinB/Cdk1 in vitro. A. Western blot analysis of nuclear (N) and
cytoplasmic (C) fractions of cells transfected with FLAG-SIRT1 expression vectors encoding wild type (WT) and mutant SIRT1 proteins. Blots were
subsequently reacted with antibodies against pericentrin and GAPDH to demonstrate the purity of the nuclear and cytoplasmic fractions,
respectively. B. Western blot analysis of WT and mutant proteins in the presence and absence of the proteasome inhibitor MG132. C/D. In vitro
kinase assays showing that threonine 530 and serine 540 are substrates for cyclinB/Cdk1 in vitro. The results are shown by autoradiograph (top
panels) and Coomassie blue stained gel (bottom panels) in (C) and by the plot of ATP incorporation (as measured by scintillation countering) vs. time
in (D).
doi:10.1371/journal.pone.0004020.g006
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leaving the cell cycle. In fact, previous studies have shown that
SIRT1-deficient mouse cells are resistant to replicative senescence
(Chua KF, et al. 2005). In cells that must retain the ability to
proliferate, SIRT1 activity would have to fluctuate according to
whether or not the cells are actively dividing. By having that
Figure 8. Phosphorylation of SIRT1 at Thr530 and Ser540 is required for normal cell cycle progression. A. Fraction of cells in M-phase of
the cell cycle in Sirt1
+/+ (blue) and Sirt1
2/2 (red) ES cells at three different time points in culture. The differences were not significant. B. Graphic
representation of the fractions of cells in each phase of the cell cycle in Sirt1
+/+ and Sirt1
2/2 ES cells transfected with empty vector (mock), WT-FLAG-
SIRT1 (WT), or AA-FLAG-SIRT1 (AA) mutant. C. Table of p-values comparing mock-transfected Sirt1
+/+ cells to Sirt1
2/2 cells transfected with empty
vector (Mock), wild-type (WT), or mutant (AA) DNA. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0004020.g008
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tion regulated by the cell cycle, a feedback loop is set up whereby
cyclin/Cdk complexes affect the activity of SIRT1, which in turn
regulates proliferation. Thus, we found that wild-type SIRT1, but
not the S540A/T530A mutant, was able to rescue the proliferation
defect in SIRT12/2 MEFs and ESCs. This is consistent with a
recent report demonstrating that forced expression of SIRT1 in
human fibroblasts increased their growth rate (Huang J, et al.
2008). The fact that SIRT1-deficient mouse cells grow more
slowly than their wild-type counterparts could in turn explain why
they are resistant to replicative senescence in culture (Chua KF, et
al. 2005). We would expect (although we did not test this) that
enhancing proliferative competence of SIRT1-deficient cells by
reintroducing wild-type SIRT1 would have the additional effect of
reinstating replicative senescence.
Although this is the first extensive report on SIRT1 phosphor-
ylation, other classes of HDACs are known to be regulated by
phosphorylation. The activities and complex formation of
HDAC1 and HDAC2 are regulated by phosphorylation [23,24],
and nucleo-cytoplasmic localization of HDAC4, HDAC5, and
HDAC7 are regulated by 14-3-3 in a phosphorylation-dependent
manner [32,33]. According to functional motif predictions
obtained through the Eukaryotic Linear Motif database [34],
Ser26 and Ser27 of human SIRT1 are within interaction motif 2
of 14-3-3, and Ser172 and Ser173 are within interaction motif 3.
Thus, it is possible that the interaction of SIRT1 with 14-3-3,
which has been demonstrated in C. elegans [35,36], is also regulated
by phosphorylation in higher organisms.
The results of our study also imply that SIRT1 might undergo
hierarchicallevelsofphosphorylation,withmultiplephosphorylation
sites cooperating to maximize subsequent phosphorylation events.
According tofunctionalmotif predictions obtained through ScanSite
(http://scansite.mit.edu) [37], KinasePhos (http://kinasephos.mbc.
nctu.edu.tw) [38], and Eukaryotic Linear Motifs (http://elm.eu.org)
[34] servers, the 13 phosphorylated residues of SIRT1 identified in
this study match target motifs for ATM, CDK5, CK1, CK2, DNA-
PK, ERK1, GSK3, IKK and MAPK, in addition to CDK1. Thus,
any number of signaling cascades could influence SIRT1 function
through the activity of various kinases and their accompanying
phosphatases. It was recently reported for HDAC7, for example,
that phosphorylation of Ser 155 is a prerequisite for phosphorylation
of Ser181 [33] and that dephosphorylation by myosin phosphatase
controls its nucleocytoplasmic shuttling and inhibits apoptosis in
thymocytes [39]. The large number of potential kinases and the
redundancy of kinases that can act on a single site could explain why
weobserved morerobustphosphorylationofSIRT1 using a ‘‘mitotic
kinase mix’’ compared to cyclinB/Cdk1 alone (Fig. 5C). The
addition of other mitotic kinases, such as aurora kinase and polo
kinase, present in the mix, significantly enhanced phosphorylation at
Cdk1-specific sites.
When SIRT1 was dephosphorylated by treatment with non-
specific phosphatases, there was a concomitant decrease in
deacetylase activity. Mutation of the Cdk1 phosphorylation sites,
however, did not lead to a reduction in deacetylase activity, at least
as measured by the Fluor-de Lys deacetylase assay. One possible
reason for this is that additional Cdk phosphorylation sites, such as
Ser14, Ser26/27, Ser47 and Ser545, or any one of the other 11
phospho-residues, may have to be mutated before loss of Cdk1
phosphorylation will affect deacetylase activity. This could explain
why the AA mutant showed a comparable amount of radioactive
ATP incorporation in the in vitro kinase assay (Fig. 6B). Another
possibility is that phosphorylation of certain residues may have
positive influence on deacetylase activity, while others may have a
negative or no influence. It should be noted that even relatively
complete dephosphorylation by non-specific phosphatases did not
totally abolish deacetylase activity (Fig. 2). Considering the fact
that all the phosphorylation sites are located outside of the
conserved catalytic domain, it is also possible that phosphorylation
of these residues could affect enzyme activity indirectly. Based on
predictions of 3D structure, Thr530 and Ser540 reside in the hinge
region of SIRT1 between the conserved core domain and the C-
terminal domain. As is clear from Fig. 1C, phosphorylation of
these residues could alter the accessibility of substrate molecules to
the catalytic groove of the deacetylase. This might be why there
were significant differences in the effects of wild-type and mutant
SIRT1 on biological phenotypes, such as cell proliferation and cell
cycle profiles, despite there being no detectable difference in
deacetylase activity between them in vitro. It should be noted that
a similar result was observed following mutation of the Cdk1 site in
SIRT2 [40], a cytoplasmic isoform of SIRT1. SIRT2 is
phosphorylated on multiple residues during the G2/M transition
and is dephosphorylated by CDC14A and CDC14B phosphatases
[40,41]. Thus, it appears that multiple sirtuins may be regulated
by cell cycle-dependent kinases.
The targets that SIRT1 deacetylates in the context of mitosis
remain undefined. CyclinB/Cdk1 kinase activity is tightly
regulated and increases during M phase of the cell cycle, yet
substrates vary and include proteins that regulate DNA replica-
tion, mitosis, spindle assembly, actin polarization, and other
processes in yeast [42]. The identification of the molecular targets
that are affected by SIRT1 phosphorylation, especially at sites
modified by cell cycle-dependent kinases like Cdk1, will help to
elucidate how changes in the level and activity of SIRT1 affect
diverse processes such as growth and longevity in organisms
ranging from single-celled yeast to mammals.
Materials and Methods
Cell culture
Sirt1
2/2 and Sirt1
+/+ ES cells (gifts from Dr. F. Alt, Harvard)
were cultured on gelatin-coated plates in DMEM supplemented
with 15% FBS, L-glutamine, non-essential amino acids, nucleo-
sides, b-mercaptoethanol, murine leukemia inhibitory factor (LIF)
(all from Millipore, Billerica, CA) and penicillin/streptomycin
(Invitrogen, Carlsbad, CA). ES cells were cultured in the absence
of feeder cells to get an accurate number for cell counting. 293T
cells were purchased from ATCC (Manassas, VA). 293T cells were
cultured as previously described [9]. For protein stability
experiments, cells were cultured for 3 hours in the presence of
the proteasome blocker MG132.
Expression vector construction and transfection
SIRT1 mutant expression vectors were generated by PCR
mutagenesis using the SIRT1-expression vector pcDNA4/TO/
FLAG-SIRT1 (a gift from Dr. D. Reinberg, NYU) [43] as a
template. The CMV promoter of the pcDNA4/TO/FLAG-
SIRT1 vector was replaced with the Pgk promoter at MluI/
EcoRV sites to allow the expression of FLAG-SIRT1 in ES cells.
For the empty pPGK vector, the pPGK-FLAGSIRT1 vector was
digested with EcoRV and PmeI to remove FLAG-SIRT1 cDNA,
and then blunt-end ligated. Plasmids were transfected using
Lipofectamine 2000 (Invitrogen) following the manufacturer’s
protocol.
Protein preparation and immunoprecipitation
Total cell lysates were prepared as previously described [9].
Immunoprecipitations of total cell lysates were performed with
FLAG-M2 beads (Sigma-Aldrich), or anti-SIRT1 N-terminal
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polyclonal antibody AS-16 (Sigma-Aldrich #S5313) and protein
G agarose (Millipore) for 2 hours or overnight. After washing 3
times with lysis buffer, SDS-PAGE and western blot analysis were
performed. FLAG-SIRT1 protein was purified by incubating
Benzonase-treated (Sigma-Aldrich) total cell lysates with anti-
FLAG M2 beads for 2 hours or overnight, then washed 3 times
with wash buffer (10% glycerol, 50 mM Tris pH 7, 150 mM
NaCl), then eluted with FLAG peptide (Sigma-Aldrich). Further
gel filtration was performed using HiLoad 6/16 Superdex 200
column and AKTA FPLC system (GE Healthcare, Piscataway,
NJ) when necessary. Samples were concentrated by centrifugation
through Microcon YM-10 filters (Millipore). GST-SIRT1 protein
was purified as previously described using BL21-CodonPlus
competent cells (Stratagene, La Jolla, CA) and the GST-SIRT1
expression vector pGEX2TK-SIRT1 (a gift from Dr. J. Smith,
UVA) [44]. The purity of the proteins was tested by western blot
and Coomassie blue staining, and the activities were measured
using the Fluor-de-Lys deacetylase assay kit (Biomol International,
Plymouth Meeting, PA). Antibodies used for the co-IP of
endogenous proteins are as described for western blot analysis
below.
Western blot analysis
Samples were separated by SDS-PAGE using 10% or 4–20%
Tris-HCl gels and transferred using standard protocols. To detect
the antigen-antibody complexes, we used Western Pico or Femto
chemiluminescence substrate (Pierce, Rockford, IL). The following
antibodies were used: Peroxidase-conjugated AffiniPure Goat-anti-
Mouse IgG and biotinylated anti-Mouse light chain (Jackson
ImmunoResearch, West Grove, PA, #115-035-100, 1:10,000),
Peroxidase-conjugated AffiniPure Goat anti-Rabbit IgG (Jackson
ImmunoResearch #110-035-144, 1:10,000), anti-Cdc2 (Cdk1)
mAb (Santa Cruz Biotechnology, Santa Cruz, CA, sc-8395,
1:1,000), anti-Cdk2 pAb (Abcam, Cambridge, MA, ab7954,
1:1,000), anti-Cdk4 pAb (Abcam ab2945, 1:1,000), anti-Cdk6
mAb (Abcam ab3126, 1:1,000), anti-cyclinA pAb (Abcam ab7956,
1:1,000), anti-cyclinB1 pAb (Abcam ab7957, 1:1,000), anti-FLAG
M2 mAb (Sigma-Aldrich F3165, 1:2,000), anti-SIRT1 N-terminal
polyclonal antibody (Millipore #07-131, 1:1,000), anti-SIRT1 C-
terminal polyclonal antibody AS-16 (Sigma-Aldrich #S5313,
1:1,000), anti-SIRT1 monoclonal antibody 2G1/F7 (Millipore
#05-707, 1:1,000), anti-phospho serine Cdk substrate antibody
(Cell Signaling Technology, Danvers, MA, #2324, 1:2,000), anti-
GAPDH antibody (Abcam ab8245, 1:5,000), and anti-pericentrin
antibody (Covance, Richmond, CA, PRB-432C, 1:300). For
Figure 4b, the ODYSSEY infrared imaging system (LI-COR,
Lincoln, NE) was used to quantitate the percentage of phosphor-
ylated SIRT1 in lppase-treated samples.
Comparative analysis of SIRT1 amino acid sequences
Amino acid sequences of SIRT1 from various species were
obtained from the NCBI database, and subjected to the BLAST 2
Sequence algorithm (http://www.ncbi.nlm.nih.gov/BLAST/)
against the human SIRT1 sequence. The following sequences
were used for the analysis: Homo sapiens (human, NP_036370), Pan
troglodytes (chimpanzee, XP_521490), Macaca mulatta (macaque
monkey, XP_001087854), Canis familiaris (domestic dog,
XP_546130), Bos taurus (cow, XP_869911), Mus musculus (mouse,
AAR23928), Rattus norvegicus (rat, XP_001080493), Gallus gallus
(chicken, NP_001004767), Drosophila melanogaster (fruit fly,
AAC79684), Caenorhabditis elegans (round worm, CAA94364),
Schizosaccharomyces pombe (fission yeast, CAG47122) and Saccharo-
myces cerevisiae (budding yeast, NP_010242).
ProQ Diamond phospho-protein staining
After protein samples were separated by SDS-PAGE and
transferred to nitrocellulose membrane, the membrane was
stained with Pro-Q Diamond phosphoprotein staining kit
(Invitrogen P-33356) following the manufacturer’s protocol.
Phospho-peptide mapping by mass spectrometry
Phospho-peptide mapping was done as previously described
[45]. The gel band containing FLAG-SIRT1 was identified by
silver stain, cut out, and the peptides generated by trypsin
treatment. Peptides were analyzed using the LC-MS system.
Structure prediction for human SIRT1
Protein sequence information for human SIRT1 (NP_036370)
was obtained from the PubMed protein database. This protein
sequence was used to derive a full chain protein structure prediction
on the Robetta server (Baker Laboratory, http://robetta.bakerlab.
org/). The Robetta server subjected the SIRT1 sequence first to the
Ginzu protocol thatdetermined putativedomainstructuresandthen
modeled those domains either by homology or by ab initio modeling.
Out of ten model predictions, the best fitting was chosen to illustrate
the full chain SIRT1. VMD1.8.6 (http://www.ks.uiuc.edu/
Research/vmd/) [46] was used for graphical illustration of the
predicted structure and the phosphorylation sites.
Phosphatase preparations and treatments
Solutions of calf intestinal phosphatase (New England Biolab,
Ipswich, MA) or lambda phosphatase (a gift from Dr. D.
Brautigan, UVA) were prepared and incubated with FLAG-
SIRT1 samples at 1:1 volume for 1 hour at 37uC unless otherwise
indicated. Phosphatase activity was blocked by adding phospha-
tase inhibitor cocktails I & II (Sigma-Aldrich) or 10 mM Na3VO4
(Sigma-Aldrich).
In vitro kinase assay
Kinase reactions were performed in 20 mM Tris HCl (pH 7.5),
1 mM MgCl2, 25 mM KCl, 1 mM DTT, and 40 mg/mL BSA,
with 100 mM of ATP spiked with c-
32P-ATP. CyclinB/Cdk1
purified from Xenopus was used with 5–10 pmole of substrate.
Samples were harvested at each time point, and reactions
quenched with 66-sample buffer. Samples were separated by
SDS-PAGE and stained with Bio-Safe Coomassie (Biorad). Gels
were photographed with ChemiImager Ready (IMGEN technol-
ogies, Alexandria, VA). After autoradiography, each protein band
was cut out of the gel and the radioactivity in the sample measured
using a Beckman LS 6000SE scintillation counter (Beckman
Coulter, Fullerton, CA). ‘‘Mitotic kinase mix’’ (a gift from Dr. D.
Brautigan, UVA) was prepared according to the protocol
described in reference [30].
Fluor-de Lys deacetylase assay
Fluor-de Lys deacetylase assay kit (Biomol International) was used
to analyze deacetylase activities in various SIRT1 preparations,
using a slight modification of the protocol recommended by the
supplier to adjust for the detection range of the fluorometer.
Nicotinamide was added to the reaction at the concentration of
2 mM when necessary. The final fluorescence was measured in a
Fluoroskan Ascent FL fluorometer (Thermo Fisher Scientific,
Waltham, MA).
Cell proliferation assay
Lipofectamine 2000 (Invitrogen) was used to transfect 1610
6 ES
cells with 2 mg of empty vector or expression vectors for FLAG-
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All vectors carried the PGK-promoter to support expression in ES-
cells. 24 hours after transfection, 2610
4 cells/well were re-plated
onto gelatin-coated 12-well plates, and cells were counted 24, 36,
48, 60, and 72 hours after replating. Each group consisted of
triplicates and the experiment was done three times, and the
average and the standard error of the number of cells in each well
were calculated. For MEFs, 5610
4 cells/well at passage 3 (split at
1:4 at each passage, used prior to immortalization) were
transfected with expression constructs driven by the CMV
promoter, and done in triplicate.
Cell cycle analysis
Cells were harvested by trypsinization, washed with phosphate-
buffered saline (PBS), and fixed in 70% ethanol at a concentration
of 10
6 cells per ml at 220uC for 2 hours or overnight. After
fixation, cells were stained with propidium iodide (Sigma-Aldrich)
and anti-phospho histone H3 (Ser10) mitosis marker antibody
(Millipore, 1:1,000) followed by Alexa 488-conjugated goat anti-
rabbit immunoglobulin G antibody (Invitrogen, 1:2,000), as
previously described [31]. Analyses were done at the University
of Virginia Flow Cytometry Facility and cell cycle distributions
were analyzed using ModiFit LT version 3.1 software (Verity
Software House, Topsham, ME). The number of cells in the G2
phase of the cell cycle was calculated by subtracting the number of
cells in M phase (determined by phospho-H3 staining) from the
number of cells in G2/M phase (determined by PI staining).
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